Sunbelt Securities Inc. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 625 shares of the life sciences company’s stock, valued at approximately $230,000.
A number of other institutional investors have also modified their holdings of the stock. Jennison Associates LLC grew its holdings in Illumina by 3.7% during the first quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock worth $1,764,619,000 after purchasing an additional 200,114 shares during the period. Geode Capital Management LLC raised its position in shares of Illumina by 10.1% in the fourth quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock valued at $555,173,000 after buying an additional 170,046 shares in the last quarter. Northern Trust Corp raised its position in Illumina by 0.9% during the first quarter. Northern Trust Corp now owns 1,660,761 shares of the life sciences company’s stock valued at $515,981,000 after purchasing an additional 14,669 shares in the last quarter. Thoroughbred Financial Services LLC raised its position in Illumina by 38,516.8% during the second quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock valued at $87,583,000 after purchasing an additional 873,560 shares in the last quarter. Finally, American Century Companies Inc. raised its position in Illumina by 107.1% during the first quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock valued at $253,484,000 after purchasing an additional 421,953 shares in the last quarter. 90.95% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have commented on ILMN shares. UBS Group boosted their price objective on shares of Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Bank of America cut shares of Illumina from a “buy” rating to an “underperform” rating and set a $310.00 target price on the stock. in a research note on Friday, July 12th. BidaskClub cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 13th. Cowen decreased their target price on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, July 12th. Finally, Wolfe Research began coverage on shares of Illumina in a research note on Thursday, May 30th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $330.92.
In related news, SVP Charles Dadswell sold 1,220 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $309.70, for a total value of $377,834.00. Following the completion of the transaction, the senior vice president now directly owns 8,006 shares of the company’s stock, valued at approximately $2,479,458.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Robert P. Ragusa sold 2,230 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $293.09, for a total transaction of $653,590.70. Following the completion of the transaction, the senior vice president now directly owns 10,685 shares of the company’s stock, valued at $3,131,666.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,458 shares of company stock valued at $16,527,618. 0.38% of the stock is owned by insiders.
ILMN traded up $0.47 on Thursday, hitting $285.54. The company’s stock had a trading volume of 21,636 shares, compared to its average volume of 1,242,876. The stock’s 50 day simple moving average is $321.15. The stock has a market cap of $41.98 billion, a price-to-earnings ratio of 50.03, a P/E/G ratio of 2.71 and a beta of 1.10. Illumina, Inc. has a 12 month low of $268.62 and a 12 month high of $380.76. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The company had revenue of $838.00 million during the quarter, compared to the consensus estimate of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. Illumina’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the firm earned $1.43 EPS. Research analysts anticipate that Illumina, Inc. will post 6.04 EPS for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: Asset Allocation Models, Which is Right For You?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.